Live attenuated coronavirus vaccines
AssigneeVanderbilt University
InventorMark Denison
Life of this patent
Estimating the term…
Abstract
The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may include other attenuating mutations. Such viruses show reduced growth and pathogenicity in vivo.
Claims32
A live, attenuated virus groups 2 coronavirus wherein said virus is characterized as comprising a genome encoding (i) an ExoN comprising a substitution at tyrosine6398 of MHV-A59, or an analogous position thereof, an (ii) an Orf2a polypeptide comprising a substitution at leu106 of MHV- A59, or an analogous position thereof.
A method of inducing an anti-viral immune response in a host comprising administering to said host a live, attentuated group 2 coronavirus wherein said virus is characterized as comprising a genome encoding (i) an ExoN comprising a substitution at tyrosine6398 of MHV-A59, or an analogous position thereof, and (ii) an Orf2a polypeptide comprising a substitution at leu106 of MHV-A59, or an analogous position thereof.
A coronavirus genome, said genome encoding an ExoN polypeptide comprising a substitution at tyrosine6398 of MHV-A59, or an analogous position thereof.
An isolated and purified nucleic acid segment encoding coronavirus ExoN polypeptide comprising comprising a substitution at tyrosine6398 of MHV-A59, or an analogous position thereof.
A composition comprising (a) a live, attentuated group 2 coronavirus, said virus characterized as comprising a genome encoding (i) an ExoN polypeptide comprising comprising a substitution at tyrosine6398 of MHV-A59, or an analogous position thereof, and (ii) an Orf2a polypeptide comprising a substitution at leu106 of MHV-A59, or an analogous position thereof, and (b) a pharmaceutically acceptable diluent.
Dependencies are inferred from the claim text.